Back to search results

Atorvastatin for Vascular Endothelial Dysfunction in Sleep Apnea

This study is looking at whether a common cholesterol-lowering medication, atorvastatin (10 mg daily), can help reduce inflammation in people with obstructive sleep apnea (OSA). OSA is a condition where breathing repeatedly stops and starts during sleep. Researchers believe atorvastatin might improve the health of blood vessel linings (endothelium) in OSA patients, even those using CPAP (Continuous Positive Airway Pressure), which is a standard treatment. You could be eligible if you are 18 or older and have been newly diagnosed with OSA, meaning you haven't used CPAP before. The study will measure specific markers in your blood, like Angiopoietin-2, and changes in cell interactions after 4 weeks to see if atorvastatin is effective. The current status of this study is unclear.

Study design
This is a double-blind, placebo-controlled study, meaning neither you nor your doctors will know if you're receiving atorvastatin or a placebo (an inactive pill). About 110 participants are planned for this study.
What's involved
You would take either atorvastatin 10 mg or a placebo daily for 28 days. CPAP will be prescribed by your regular care providers, separate from this study.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure specific markers after 4 weeks of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05289063

Vascular Endothelial Dysfunction in Sleep Apnea

Recruiting
PHASE1Ages 18+InterventionalBasic science
Columbia University
~110 participants
Updated 2026-02-13 on ClinicalTrials.gov
What's tested:Atorvastatin 10mgPlaceboContinuous Positive Airway Pressure Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Circulating levels of Angiopoietin-2 after 4 weeks of atorvastatin vs. placebo therapy
Measured over 4 weeks post-treatment
+1 more outcome measured

Conditions

Obstructive Sleep Apnea of Adult

Explore related trials

Obstructive Sleep Apnea

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Sanja Jelic, MD · PRINCIPAL_INVESTIGATOR · Columbia University

Who to contact

Sanja Jelic, MD
[email protected]
2125438875
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged ≥18 years
Newly diagnosed with obstructive sleep apnea (OSA) who were never treated with CPAP. OSA is defined as apnea-hypopnea index (AHI) ≥5 events/hour of sleep.

Exclusion

A history of coronary artery disease, heart failure, stroke, diabetes, malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain/fatigue, smoking within the past 5 years
Regular use of any medications

What this trial measures

  • Circulating levels of Angiopoietin-2 after 4 weeks of atorvastatin vs. placebo therapy4 weeks post-treatment

    Mean circulating levels of Ang-2 will be quantified after 4 weeks of statin or placebo therapy by enzyme-linked immunosorbent assay (ELISA)

  • Interaction of endoplasmic reticulum (ER)-bound vesicle-associated membrane protein-associated protein B (VAPB) with late endosome-bound ORP1L (proximity ligation assay fluorescence area in µm2) after 4 weeks of atorvastatin vs. placebo therapy4 weeks post-treatment

    Mean Interactions ER-bound VAPB with late endosome-bound ORP1L in harvested endothelial cells (ECs) will be assessed using proximity ligation assay (DuoLink, fluorescence area in µm2) after 4 weeks of atorvastatin or placebo therapy